Posted by Michael Wonder on 08 Mar 2023
FDA accepts Novan’s NDA for berdazimer 10.3% topical gel for the treatment of molluscum contagiosum
7 March 2023 - FDA completes filing review of application with no filing issues identified.
Novan today announced that the US FDA accepted for filing Novan’s new drug application seeking approval for berdazimer gel, 10.3% (SB206) for the treatment of molluscum contagiosum.
The Company also received its PDUFA goal date of 5 January 2024.
